QIAGEN announces the winner of the 2017 Microbiome Awards
The Microbiome Awards provide products and recognition to scientists in the microbiome field
HILDEN, Germany – QIAGEN today announced that Dr. Michael Montague of the University of Pennsylvania is the winner of the 2017 Microbiome Awards. The Microbiome Awards aim to provide extraordinary scientists with products and recognition to carry out scientific work in the field of microbiome research.
Dr. Montague’s project aims to study the brain-gut network in free-ranging macaques to understand the effects of social integration on microbial diversity and serotonin synthesis. Dr. Montague is a Postdoctoral Associate in the laboratory of Dr. Michael Platt at the University of Pennsylvania in Philadelphia, PA, USA.
Dr. Montague will receive a research package consisting of the following: a two-year license to Microbial Genomics Pro Suite, analysis of 250 samples using the Cosmos ID Genomics Platform, NGS Library Prep of 96 samples using any NGS library prep kit or $3000 USD NGS library prep services, sample Prep of 400 samples using any DNA or RNA isolation Kit or $3000 USD in sample prep services, and a QIAcube instrument.
The judging panel for the Microbiome Awards consisted of independent, distinguished representatives from various institutions and universities who are currently leading the field of microbiome research. The panel included world renowned microbiome scientists Lauren Ambrogio from AOBiome, Elizabeth Bik from uBiome, David Coil from the University of California, Davis, and Emily Hollister from Baylor College of Medicine.
More details about Dr. Montague’s award-winning project can be found at https://mobio.com/microbiome_
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2016, QIAGEN employed approximately 4,700 people in over 35 locations worldwide. Further information can be found athttps://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
